Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

Wien Klin Wochenschr. 2022 Oct;134(19-20):683-692. doi: 10.1007/s00508-022-02082-3. Epub 2022 Sep 23.


In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.

Keywords: Advanced breast cancer; Antibody-drug conjugates; Erbb2; Systemic therapy; Tyrosin kinase inhibitors.

MeSH terms

  • Algorithms
  • Austria
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Neoplasms, Second Primary*
  • Receptor, ErbB-2 / therapeutic use


  • Receptor, ErbB-2